Moderna (MRNA) Capital Leases (2017 - 2025)
Historic Capital Leases for Moderna (MRNA) over the last 9 years, with Q3 2025 value amounting to $26.0 million.
- Moderna's Capital Leases fell 9584.0% to $26.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.0 million, marking a year-over-year decrease of 9584.0%. This contributed to the annual value of $39.0 million for FY2024, which is 9321.74% down from last year.
- Latest data reveals that Moderna reported Capital Leases of $26.0 million as of Q3 2025, which was down 9584.0% from $32.0 million recorded in Q2 2025.
- Moderna's Capital Leases' 5-year high stood at $922.0 million during Q3 2022, with a 5-year trough of $26.0 million in Q3 2025.
- Moreover, its 5-year median value for Capital Leases was $575.0 million (2023), whereas its average is $481.9 million.
- As far as peak fluctuations go, Moderna's Capital Leases skyrocketed by 44454.55% in 2021, and later plummeted by 9584.0% in 2025.
- Quarter analysis of 5 years shows Moderna's Capital Leases stood at $599.0 million in 2021, then soared by 52.25% to $912.0 million in 2022, then plummeted by 36.95% to $575.0 million in 2023, then tumbled by 93.22% to $39.0 million in 2024, then crashed by 33.33% to $26.0 million in 2025.
- Its last three reported values are $26.0 million in Q3 2025, $32.0 million for Q2 2025, and $35.0 million during Q1 2025.